{"schema":"sb.node.v1","id":"sb:e/75a609d6ef4db497455bafef","kind":"entity","label":{"text":"european association","locale":"en"},"identity":{"anchor":"label:en:european association","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T23:27:45.667496+00:00","snapshot":"deploy 56227b222ea0ec405925ec2672b91c66e5fd51a0"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":55,"separatePublishers":28,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.182,"named":10,"of":55,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 18% of the 55 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-03","to":"2026-10-09","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.073: about 93% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto"],"activeDays":23,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":10,"byKind":{"observation":10},"items":[{"id":"sb:o/07f99d7f8a650799b64dc4c9","kind":"observation","label":"PR Newswire · 2026-10-04 · SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026","url":"https://www.prnewswire.com/news-releases/sibionics-and-pharmasens-explore-new-horizons-for-automated-insulin-delivery-at-easd-2026-302897720.html"},{"id":"sb:o/39741ef936c56c8b781b4743","kind":"observation","label":"Medical Xpress · 2026-10-02 · Low-calorie diet and exercise put early-onset type 2 diabetes in remission for 54% of participants","url":"https://medicalxpress.com/news/2026-10-calorie-diet-early-onset-diabetes.html"},{"id":"sb:o/f8bb39d30176a60ed0954b8f","kind":"observation","label":"The Medical News · 2026-10-01 · Real-world data reveals higher reported GLP-1 side effects in female patients","url":"https://www.news-medical.net/news/20261001/Real-world-data-reveals-higher-reported-GLP-1-side-effects-in-female-patients.aspx"},{"id":"sb:o/187909d9eb75ad761d2e4fdc","kind":"observation","label":"Medical Xpress · 2026-10-01 · New triple agonist drug produces substantial weight loss in diabetic patients","url":"https://medicalxpress.com/news/2026-10-triple-agonist-drug-substantial-weight.html"},{"id":"sb:o/e176cf252fa229029ab9dcd5","kind":"observation","label":"The Medical News · 2026-10-01 · GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes","url":"https://www.news-medical.net/news/20261001/GLP-1-receptor-agonist-exposure-shows-no-link-to-major-adverse-pregnancy-outcomes.aspx"},{"id":"sb:o/eac8a8bbb28485e6d35ca43e","kind":"observation","label":"The Medical News · 2026-10-01 · Early-onset type 2 diabetes trial demonstrates significant 24-week fat loss","url":"https://www.news-medical.net/news/20261001/Early-onset-type-2-diabetes-trial-demonstrates-significant-24-week-fat-loss.aspx"},{"id":"sb:o/3455378ae89397041503ee36","kind":"observation","label":"Fierce Pharma · 2026-09-30 · Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan","url":"https://www.fiercepharma.com/pharma/novo-lilly-pit-their-glp-1s-against-one-another-diabetes-and-obesity-easd-kicks-milan"},{"id":"sb:o/9e7554b88a454340c22f3964","kind":"observation","label":"The Medical News · 2026-09-28 · Research makes strong case for broader use of GLP1 drugs to protect hearts","url":"https://www.news-medical.net/news/20260928/Research-makes-strong-case-for-broader-use-of-GLP1-drugs-to-protect-hearts.aspx"},{"id":"sb:o/e6908f08c8e9b490c74ae9e5","kind":"observation","label":"The Medical News · 2026-09-28 · New diabetes pill orforglipron achieves uniform weight loss for women of all ages","url":"https://www.news-medical.net/news/20260928/New-diabetes-pill-orforglipron-achieves-uniform-weight-loss-for-women-of-all-ages.aspx"},{"id":"sb:o/6f2d026a68074f5f15d5e5c5","kind":"observation","label":"The Medical News · 2026-09-28 · New EASD study highlights red meat sugar as independent risk factor for type 2 diabetes","url":"https://www.news-medical.net/news/20260928/New-EASD-study-highlights-red-meat-sugar-as-independent-risk-factor-for-type-2-diabetes.aspx"}],"cursor":null,"order":"newest first; we keep the 10 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with annual meeting (29 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/af8b26b03f0d4c42342baa99"},{"kind":"relation","label":"co-mentioned with italy (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/448e1e399e7a88e03b7c35ee"},{"kind":"relation","label":"co-mentioned with glp-1 (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/829373c11fca1e73860b8db8"},{"kind":"relation","label":"co-mentioned with easd (22 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/64f04722c85ebed338bfcedf"},{"kind":"relation","label":"co-mentioned with eli lilly (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c7a747c6bdb9a633cc7a6652"},{"kind":"relation","label":"co-mentioned with europe (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/eb50d8d53b8591f7272fbe0a"},{"kind":"relation","label":"co-mentioned with fda (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9339ca7a9261f881147c4d5c"},{"kind":"relation","label":"co-mentioned with adverse events (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0e1982ad215980fe9ba9d237"},{"kind":"relation","label":"co-mentioned with hba1c (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4b1f6b3321c64df036610368"},{"kind":"relation","label":"co-mentioned with china (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2387fe7811e991216fa39604"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/75a609d6ef4db497455bafef","mcp":"traverse {\"id\":\"sb:e/75a609d6ef4db497455bafef\"}","page":"/entity/european-association/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/75a609d6ef4db497455bafef\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/75a609d6ef4db497455bafef\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/75a609d6ef4db497455bafef\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/75a609d6ef4db497455bafef\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}